[Biopharmaceutic properties of slow-release codeine phosphate. Drug release from ion exchangers in vitro and in vivo].
The release of bound codeine (CAS 76-57-3) from a cation exchanger was examined in vitro by the flow-through method and in vivo by measuring the plasma concentrations of codeine after administration of slow-release (Codipront Retard) and standard non-retarded drops. Both sets of results show that codeine release from the ion exchanger is protracted and continuous. Relative to the standard formulation the slow-release codeine drops give a lower maximal plasma concentration (Cmax), a delayed time of maximal concentration (tmax), slower absorption (t0.5) and protracted plasma levels. The in vitro and in vivo results were in good agreement.
Wildfeuer
A
A
Pfizer/Heinrich Mack Nachfolger, Forschung und Entwicklung, Illertissen.
Pfaff
G
G
Lach
P
P
D000328:Adult; D001702:Biopharmaceutics; D003061:Codeine / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007408:Intestinal Absorption; D007474:Ion Exchange; D008297:Male; D012995:Solubility
D003692:Delayed-Action Preparations; D003061:Codeine
Biopharmazeutische Eigenschaften von retardiertem Codeinphosphat. Untersuchung der Wirkstoff-Freisetzung eines Ionenaustauschers in vitro und in vivo.